S. Senan Et Al. , "Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial," ESMO OPEN , vol.7, no.2, 2022
Senan, S. Et Al. 2022. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO OPEN , vol.7, no.2 .
Senan, S., ÖZGÜROĞLU, M., Daniel, D., Villegas, A., Vicente, D., Murakami, S., ... Hui, R.(2022). Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO OPEN , vol.7, no.2.
Senan, S. Et Al. "Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial," ESMO OPEN , vol.7, no.2, 2022
Senan, S. Et Al. "Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial." ESMO OPEN , vol.7, no.2, 2022
Senan, S. Et Al. (2022) . "Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial." ESMO OPEN , vol.7, no.2.
@article{article, author={S. Senan Et Al. }, title={Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial}, journal={ESMO OPEN}, year=2022}